Skip to main content

Table 1 Genetically modified recombinant clostridial strains and their antitumour studies.

From: Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems

Recombinant Strain Model Strategy/Result Reference
C. oncolyticum/sporogenesrecombinant for E. coli colicin E3 In vitro study Cancerostatic properties [56]
C. beijerinckii (acetobutylicum) recombinant for E. coli cytosine deaminase (CDase) In vitro study and tested on murine EMT6 carcinoma cell-line Sensitivity to 5-fluorocytosine increased 500-fold [72]
C. beijerinckii (acetobutylicum) recombinant for Nitroreductase (NTR) EMT6 Mouse
Prodrug: CB1954
CDEPT strategy with CB1954
Nitroreductase activity detected in tumor lysate
C. acetobutylicum recombinant for Tumour necrosis factor (TNF-α) Rhabdomyosarcoma Recombinant protein detected in tumour, but no control of tumour growth [58]
C. acetobutylicum recombinant for E. coli cytosine deaminase (CDase) Rhabdomyosarcoma
Prodrug: 5-FC
CDEPT strategy
Cytosine deaminase activity detected in tumor lysate
C. sporogenes recombinant for cytosine deaminase (CDase) SCCVII tumours into syngeneic C3H/Km mice
Prodrug 5-FC
Growth delay of tumours [57]
C. acetobutylicum recombinant for interleukin-2 (IL-2) Rhabdomyosarcoma Enhanced antitumour effect [60
C. sporogenes and C. novyi-NT recombinant for Nitroreductase (NTR) Human colorectal carcinoma (HCT116) CDEPT strategy with CB1954
High level of colonization 108–109 cfu/g tumour.
Repeated CDEPT treatment cycle, significant tumour growth delay
  1. Description of additional data files (N/A)